Korea Investment CORP Has $4.73 Million Stock Position in Solventum Corporation $SOLV

Korea Investment CORP lowered its stake in Solventum Corporation (NYSE:SOLV) by 48.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,207 shares of the company’s stock after selling 58,500 shares during the period. Korea Investment CORP’s holdings in Solventum were worth $4,730,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Trian Fund Management L.P. boosted its position in Solventum by 18.8% in the fourth quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company’s stock valued at $559,054,000 after buying an additional 1,336,564 shares in the last quarter. Davis Selected Advisers grew its stake in shares of Solventum by 0.8% in the first quarter. Davis Selected Advisers now owns 5,288,138 shares of the company’s stock worth $402,110,000 after purchasing an additional 41,524 shares during the last quarter. Boston Partners increased its holdings in Solventum by 101.3% in the first quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after purchasing an additional 1,691,565 shares during the period. Northern Trust Corp increased its holdings in Solventum by 3.3% in the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock valued at $137,456,000 after purchasing an additional 58,373 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Solventum by 2.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company’s stock worth $89,268,000 after purchasing an additional 24,762 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Wall Street Zen upgraded Solventum from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. KeyCorp initiated coverage on shares of Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating on the stock. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Piper Sandler restated an “overweight” rating and issued a $94.00 target price (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Finally, Wells Fargo & Company upped their price target on shares of Solventum from $75.00 to $79.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $85.75.

Solventum Trading Up 2.0%

NYSE:SOLV opened at $73.46 on Friday. Solventum Corporation has a 12 month low of $59.35 and a 12 month high of $85.92. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The stock has a market capitalization of $12.74 billion, a price-to-earnings ratio of 34.01, a PEG ratio of 1.74 and a beta of 0.52. The firm has a fifty day simple moving average of $73.79 and a two-hundred day simple moving average of $72.87.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the prior year, the business earned $1.56 EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.